Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Although tumor surveillance by T and B lymphocytes is well studied, the role of innate immune cells, in particular macrophages, is less clear. Moreover, the existence of subclonal genetic and functional diversity in some human cancers such as leukemia underscores the importance of defining tumor surveillance mechanisms that effectively target the disease-sustaining cancer stem cells in addition to bulk cells. In this study, we report that leukemia stem cell function in xenotransplant models of acute myeloid leukemia (AML) depends on SIRPα-mediated inhibition of macrophages through engagement with its ligand CD47. We generated mice expressing SIRPα variants with differential ability to bind human CD47 and demonstrated that macrophage-mediated phagocytosis and clearance of AML stem cells depend on absent SIRPα signaling. We obtained independent confirmation of the genetic restriction observed in our mouse models by using SIRPα-Fc fusion protein to disrupt SIRPα–CD47 engagement. Treatment with SIRPα-Fc enhanced phagocytosis of AML cells by both mouse and human macrophages and impaired leukemic engraftment in mice. Importantly, SIRPα-Fc treatment did not significantly enhance phagocytosis of normal hematopoietic targets. These findings support the development of therapeutics that antagonize SIRPα signaling to enhance macrophage-mediated elimination of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Self-citationSacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.025 · Cited by 2,226
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · cited 4×
“This hypothesis is supported by evidence that high CD47 expression in AML is associated with poor clinical outcome and that treatment of NS mice bearing human AML grafts with an anti-CD47 antibody (Ab) reduces leukemic engraftment (Majeti et al., 2009).”
MethodInfluentialDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 1×
“In contrast to the function of classically activated macrophages in tumor immune surveillance, tumor-associated macrophages have been implicated in the progression of both solid tumors and hematologic malignancies through promotion of tumor vascularization, invasion, metastasis, and resistance to chemotherapy (Ruhrber…”
Winkler, I. G., Sims, N. A., Pettit, A. R., Barbier, V., Nowlan, B., Helwani, F., Poulton, I. J., van Rooijen, N., Alexander, K. A., Raggatt, L. J., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253534 · Cited by 801
Cited by
Barclay, A. N., & van den Berg, T. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120142 · Cited by 841
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Macrophage-Based Approaches for Cancer Immunotherapy
Anderson, N. R., Minutolo, N. G., Gill, S., & Klichinsky, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2990 · Cited by 698
Cancer stem cell–immune cell crosstalk in tumour progression
Bayik, D., & Lathia, J. D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00366-w · Cited by 561
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis
Koh, E., Lee, E. J., Nam, G.-H., Hong, Y., Cho, E., Yang, Y., & Kim, I.-S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.004 · Cited by 365
Cancer immunotherapy targeting the CD47/SIRPα axis
Weiskopf, K. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.013 · Cited by 353
Therapeutic targeting of acute myeloid leukemia stem cells
Pollyea, D. A., & Jordan, C. T. (2017) · Blood · doi:10.1182/blood-2016-10-696039 · Cited by 299
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Chen, J., Zhong, M.-C., Guo, H., Davidson, D., Mishel, S., Lu, Y., Rhee, I., Pérez-Quintero, L.-A., Zhang, S., Cruz-Munoz, M.-E., et al. (2017) · Nature · doi:10.1038/nature22076 · Cited by 288
Self-citationPetrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1700 · Cited by 278
Self-citationMacrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J.-P., Ho, P. Y., McKenna, K. M., Cheshier, S., Zhang, M., Guo, N., Gip, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424907112 · Cited by 253
Kauder, S. E., Kuo, T. C., Harrabi, O., Chen, A., Sangalang, E., Doyle, L., Rocha, S. S., Bollini, S., Han, B., Sim, J., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201832 · Cited by 168
Humanized hemato-lymphoid system mice
Theocharides, A. P. A., Rongvaux, A., Fritsch, K., Flavell, R. A., & Manz, M. G. (2016) · Haematologica · doi:10.3324/haematol.2014.115212 · Cited by 166
Self-citation
Metadata
- Authors
- Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J. M., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., Dick, J. E., & Wang, J. C. Y.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-09-03
- Volume
- 209
- Issue
- 10
- Pages
- 1883-1899
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2102527135
- Cited by
- 137
- References
- 6
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.